Esperion Therapeutics Inc ESPR

Healthcare

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

NDAQ:ESPR - Post by User

Esperion Therapeutics Inc

Bullboard Posts

Post by BearDownAZon Jan 12, 2017 10:43am

65 Views

Post# 25699053

ESPR Trial Launches and New Releases 1/8/17 and 1/9/17

ESPR announces initiation of three pivotal Phase 3 LDL cholesterol studies for Bempedoic Acid. Top-line results from the global Phase 3 program for Bempedoic Acid are expected by mid-2018. Study details here:
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid

ESPR initiates CLEAR Outcomes cardiovascular outcomes trial for Bempedoic Acid in patients considered Statin Intolerant. The study is expected to enroll over a 30-month period with a total estimated study duration of approximately 4.75 years. Study details here:
Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale